Greek real-world cohort reports 19.9% weight loss on tirzepatide at 12 months

The wire

1. 01Among 249 adults treated with individualized tirzepatide dosing, mean 12-month weight loss was 19.9% plus or minus 8.6%, with 88.9%, 50.0% and 27.2% reaching 10%, 20% and 25% thresholds.
2. 02For clinicians, six-month response predicted reaching 20% loss at 12 months (AUC 0.760; adjusted OR 1.34 per percentage point), useful when counseling slower responders.
3. 03Retrospective and observational, with 25.7% confirmed discontinuation and 6.0% lost to follow-up; the authors say the data do not establish weight maintenance beyond 12 months.

From the source

12-month weight-loss trajectories and predictors of response to tirzepatide under individualized dosing: A multicenter real-world study

Obesity pillars · 2026 Dec · Angelopoulos N, Fousteris E, Zianni D et al.